Education
About Us
Working with TipRanks
Follow Us
Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
Total Valuation
Corbus Pharmaceuticals has a market cap or net worth of $118.02M. The enterprise value is -$29.96M.
Market Cap$118.02M
Enterprise Value-$29.96M
Share Statistics
Corbus Pharmaceuticals has 12,255,225 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,255,225
Owned by Insiders31.74%
Owned by Institutions1.49%
Financial Efficiency
Corbus Pharmaceuticals’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -33.45%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.26
Return on Invested Capital (ROIC)-33.45%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee0.00
Profits Per Employee-1.44M
Employee Count28
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Corbus Pharmaceuticals is ―. Corbus Pharmaceuticals’s PEG ratio is 0.05.
PE Ratio―
PS Ratio0.00
PB Ratio0.90
Price to Fair Value0.90
Price to FCF-3.08
Price to Operating Cash Flow-2.19
PEG Ratio0.05
Income Statement
In the last 12 months, Corbus Pharmaceuticals had revenue of 0.00 and earned -40.21M in profits. Earnings per share was -3.68.
Revenue0.00
Gross Profit0.00
Operating Income-48.72M
Pretax Income-40.21M
Net Income-40.21M
EBITDA-37.74M
Earnings Per Share (EPS)-3.68
Cash Flow
In the last 12 months, operating cash flow was -57.90M and capital expenditures 0.00, giving a free cash flow of -57.90M billion.
Operating Cash Flow-57.90M
Free Cash Flow-57.90M
Free Cash Flow per Share-4.72
Dividends & Yields
Corbus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.97
52-Week Price Change-82.46%
50-Day Moving Average8.59
200-Day Moving Average9.98
Relative Strength Index (RSI)61.97
Average Volume (3m)114.07K
Important Dates
Corbus Pharmaceuticals upcoming earnings date is Nov 11, 2025, TBA (Confirmed).
Last Earnings DateAug 5, 2025
Next Earnings DateNov 11, 2025
Ex-Dividend Date―
Financial Position
Corbus Pharmaceuticals as a current ratio of 12.94, with Debt / Equity ratio of 2.25%
Current Ratio12.94
Quick Ratio12.94
Debt to Market Cap0.01
Net Debt to EBITDA0.37
Interest Coverage Ratio-26.03
Taxes
In the past 12 months, Corbus Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Corbus Pharmaceuticals EV to EBITDA ratio is -3.04, with an EV/FCF ratio of -2.75.
EV to Sales0.00
EV to EBITDA-3.04
EV to Free Cash Flow-2.75
EV to Operating Cash Flow-2.75
Balance Sheet
Corbus Pharmaceuticals has $20.04M in cash and marketable securities with $2.46M in debt, giving a net cash position of -$17.59M billion.
Cash & Marketable Securities$20.04M
Total Debt$2.46M
Net Cash-$17.59M
Net Cash Per Share-$1.44
Tangible Book Value Per Share$13.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Corbus Pharmaceuticals is $42.29, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$42.29
Price Target Upside339.15% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast18.15%